These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 278414)

  • 1. [Status of plasma blood clotting factors during different stages of erythromyelosis in rats and the effect of hexaphosphamide on the indices studied].
    Stepanian MA; Chilingarian AG; Muradian LB
    Zh Eksp Klin Med; 1978; 18(2):24-8. PubMed ID: 278414
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of experimental and clinical studies of a new antileukemic drug: hexaphosphamide. Review of the literature and the author's own results].
    Khomchenovskii EI
    Haematologia (Budap); 1977; 11(1-2):115-26. PubMed ID: 352850
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of hexaphosphamide for the treatment of myelocytic leukemia].
    Nevskaia TP; Levitin EI; Mokeeva RA; Faĭnshteĭn FE
    Probl Gematol Pereliv Krovi; 1976 Jul; 21(7):57. PubMed ID: 1071794
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of various antitumor drugs on developing Schwez erythromyelosis in rats].
    Emanuel' NM; Dronova LM; Erokhin VN; Belich EI
    Izv Akad Nauk SSSR Biol; 1970; 1():87-92. PubMed ID: 5275614
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of hexaphosphamide on the cellular cycle of mouse lympholeukemia L-1210].
    Egorov LV; Gerasimova NA; Kozinets GI; Zaretskiĭ II
    Probl Gematol Pereliv Krovi; 1976 Mar; 21(3):30-3. PubMed ID: 995892
    [No Abstract]   [Full Text] [Related]  

  • 6. [Characteristics of antineoplastic activity of some chemical compounds on the kinetic model of erythromyelosis in rats].
    Emanuél' NM; Dronova NM; Erokhin VN; Belich EI
    Izv Akad Nauk SSSR Biol; 1968; 2():181-91. PubMed ID: 5261112
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
    Schiffer CA; Davis RB; Mayer RJ; Peterson BA; Lee EJ
    Cancer Treat Rep; 1987 Sep; 71(9):879-80. PubMed ID: 3621225
    [No Abstract]   [Full Text] [Related]  

  • 8. [Stable drug resistance to paraphenacyl in a strain of rats with transplanted leukemia (erythromyelosis)].
    Khomchenovskiĭ EI
    Biull Eksp Biol Med; 1968; 65(6):71-4. PubMed ID: 5273159
    [No Abstract]   [Full Text] [Related]  

  • 9. [A comparative quantitative study of the anti-leukemia activity of hexaphosphamide, various anti-leukemia preparations and x-rays].
    Khomchenovskiĭ EI
    Biull Eksp Biol Med; 1968 Apr; 65(4):90-3. PubMed ID: 4991414
    [No Abstract]   [Full Text] [Related]  

  • 10. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
    Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
    Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
    [No Abstract]   [Full Text] [Related]  

  • 11. The antineoplastic activity of hexaziridinocyclotriphosphazene (Myko 63) in murine tumors.
    Malfiore C; Marmonti L; Filippeschi S; Labarre JF; Spreafico F
    Anticancer Res; 1983; 3(6):425-9. PubMed ID: 6230986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of diaziquone in advanced renal adenocarcinoma.
    Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M
    Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy of chronic lymphocytic leukemia].
    Gerhartz H
    Med Klin; 1967 Aug; 62(32):1237-9. PubMed ID: 4969643
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biological effects of leakadin].
    Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
    Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [On the treatment of hemoblastoses with N-diethyleneimidophosphonyl-N-phenylurea (C 73)].
    Gerhartz H; Staeuber PG
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1965; 83(1):54-61. PubMed ID: 4157882
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
    McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
    Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
    Frytak S; Eagan RT; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of diaziquone in malignant mesothelioma.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Nichols WC
    Cancer Treat Rep; 1986 Mar; 70(3):429. PubMed ID: 3955559
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
    Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.